Cases & Deals

  • Home
  • Practices
  • Bristol Myers Squibb participates in $37 million financing of EvolveImmune Therapeutics

Share

Bristol Myers Squibb participates in $37 million financing of EvolveImmune Therapeutics

November 2023

Client(s) Bristol Myers Squibb Company

Jones Day advised Bristol Myers Squibb in connection with the $37 million financing of EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immune therapy agents.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.